Seeking Alpha

NPS Pharmaceuticals CEO (NPSP -2.9%) Francois Nader tells Minyanville that its drug aimed at...

NPS Pharmaceuticals CEO (NPSP -2.9%) Francois Nader tells Minyanville that its drug aimed at treating hypoparathyroidism will be successful following positive clinical testing of the treatment, helping offset problems with its experimental Gattex drug. Stifel Nicolaus expects both drugs to eventually win US approval, setting a price target of $11 on shares. Leerink Swann aims even higher with a $14-$16 price target - repping a tripling of the stock's current value.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|